The m 6 A ‐independent role of epitranscriptomic factors in cancer
International Journal of Cancer · 2024
DOI: 10.1002/ijc.35067 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Guglielmo Bove und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy. Hauptthemen laut MEDLINE: Neoplasms, Adenosine, Epigenesis, Genetic, Methyltransferases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Centre for Gene Therapy and Drugs Based on RNA Technology, PNRR Project ANTHEM (AdvaNced Technologies for Human-cEntred Medicine), NextGenerationEU.
Abstract (Originalsprache)
Protein function alteration and protein mislocalization are cancer hallmarks that drive oncogenesis. N 6 ‐methyladenosine (m 6 A) deposition mediated by METTL3 , METTL16 , and METTL5 together with the contribution of additional subunits of the m 6 A system, has shown a dramatic impact on cancer development. However, the cellular localization of m 6 A proteins inside tumor cells has been little studied so far. Interestingly, recent evidence indicates that m 6 A methyltransferases are not always confined to the nucleus, suggesting that epitranscriptomic factors may also have multiple oncogenic roles beyond m 6 A that still represent an unexplored field. To date novel epigenetic drugs targeting m 6 A modifiers, such as METTL3 inhibitors, are entering into clinical trials, therefore, the study of the potential onco‐properties of m 6 A effectors beyond m 6 A is required. Here we will provide an overview of methylation‐independent functions of the m 6 A players in cancer, describing the molecular mechanisms involved and the future implications for therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
- Prinses Máxima Centrum, Utrecht, The Netherlands.
- Program of Medical Epigenetics, Vanvitelli Hospital, Naples, Italy.
- BIOGEM, Via Camporeale, Ariano Irpino, Italy.
- IEOS-CNR Institute for Endocrinology and Oncology "Gaetano Salvatore", Naples, Italy.
ORCID-Profile: Nunzio Del Gaudio
Förderung
- National Centre for Gene Therapy and Drugs Based on RNA Technology
- PNRR Project ANTHEM (AdvaNced Technologies for Human-cEntred Medicine)
- NextGenerationEU
- EPI-MET Fondo Crescita Sostenibile-Accordi per l'Innovazione
- Bando di Ateneo per il finanziamento di progetti di ricerca fondamentale ed applicata dedicato ai giovani Ricercatori
- VALERE: Vanvitelli per la Ricerca Program: EPInhibitDRUGre
- PON Ricerca e Innovazione 2014-2020 Linea 1, AIM
- University of Campania "Luigi Vanvitelli," Doctoral Programme in Translational Medicine
Zitieren
APA
Bove, G., Crepaldi, M., Amin, S., Megchelenbrink, W. L., Nebbioso, A., Carafa, V., Altucci, L., & Del Gaudio, N. (2024). The m 6 A ‐independent role of epitranscriptomic factors in cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.35067
Vancouver
Bove G, Crepaldi M, Amin S, Megchelenbrink WL, Nebbioso A, Carafa V, et al. The m 6 A ‐independent role of epitranscriptomic factors in cancer. International Journal of Cancer. 2024. doi:10.1002/ijc.35067
BibTeX
@article{Bove2024,
author = {Bove, Guglielmo and Crepaldi, Marco and Amin, Sajid and Megchelenbrink, Wouter Leonard and Nebbioso, Angela and Carafa, Vincenzo and Altucci, Lucia and Del Gaudio, Nunzio},
title = {The m 6 A ‐independent role of epitranscriptomic factors in cancer},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.35067}
}
EUVIMED